A slate of new biomarkers developed to diagnose Alzheimer's at an early stage may revolutionize drug development work in the field. After years of study investigators have concluded that the dementia associated with the disease comes at the end of a lengthy process. But biomarkers that can be detected through brain scans, MRIs and spinal taps present a new opportunity to identify the disease early on, creating a big opening to slow or even stop disease progression before it blights a patient's life. Article